Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

AFib patients able to safely transition from warfarin to a DOAC

The new analysis, published in the Journal of the American Heart Association, explored what happens with AFib patients shift their anticoagulant strategy.

Black, Hispanic AFib patients less likely to start anticoagulant therapy, new VA study finds

Researchers wrote that they hope their findings can help guide the creation of policies that reduce disparities in care for AFib patients.

High-dose icosapent ethyl treatment makes minimal impact on non-hospitalized COVID-19 patients

The analysis, presented at AHA Scientific Sessions 2021, included approximately 2,000 symptomatic COVID-19 patients who were not necessarily sick enough to be hospitalized.

Statin use may increase the risk of severe illness among COVID-19 patients

The new analysis emphasized, however, that COVID-19 mortality did not appear to be affected by prior statin use.

Many nonvalvular AFib patients skip DOAC therapy altogether

The study's authors hope their work can help with the development of new interventions that target this issue.

The exact effect of statin use on COVID-19 outcomes remains unclear

Researchers examined data from nearly 470,000 patients.

Half-dose DOAC improves outcomes after LAAO

The new-look anticoagulation strategy was associated with a significant reduction in adverse outcomes.

FDA announces recall of 2 hypertension medications

The affected batches were distributed from October 2018 to December 2020.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes